York, England and Rochester, NY, March 27, 2007 – ACM-Pivotal, the global central laboratory that continually defines the customer-service standard with its inherently flexible approach, today announced strong growth across its global operations that has resulted in new strategic appointments and significantly upgraded facilities in its U.S. lab in Rochester, NY. ACM-Pivotal has experienced substantial growth with its existing client base, as well as new pharmaceutical and biotechnology companies, that have recognized the benefits of its proven processes to keep clinical trials on schedule. Attendees can visit ACM-Pivotal at the Institute of Clinical Research’s 28th Annual Conference and Exhibition in Birmingham, UK this week.
Since joining forces in 2004, the organization’s total workforce has grown by 20 percent, which includes new staff in project and data management, business development and analytical services. In addition, the U.S. facility in Rochester, NY has expanded its space to 70,000 sq. ft. by adding a 15,500 sq. ft. new third floor. The expansion more efficiently supports the current and anticipated growth of the business on a global basis. Currently, ACM-Pivotal’s global operations extend to more than 60 countries, including the Americas, Europe, including Eastern Europe and Russia, Australia, Asia, Israel and South Africa – with all tests conducted and managed from central lab facilities with seamless data management providing a single database. Last year, the organization expanded its capabilities to conduct trials in India.
“We are making a significant impact in this industry because of our consistent and extremely high customer-service standard, world-class analytical capabilities and global reach,” said Elena Logan, VP of Clinical Trials, ACM-Pivotal, US. “We strive to build long-lasting relationships with our clients, and this growth is further validation that our clients value the peace of mind they’ve become accustom to as a result of our high-calibre teams and superior service.”
Over the past year, ACM-Pivotal has enhanced its track record with trials in oncology, female health, metabolic syndrome and infectious diseases, and has continued to invest in its analytical capabilities. The organization recently announced an expanded Pathology Services department as part of its central facility to more consistently and cost-efficiently respond to all testing needs. It is also currently expanding its flow cytometry department to meet a significant increase in demand for this highly specialized discipline. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting.
“There has been a growing trend towards more global clinical trials over many years, with a continual desire to expand into emerging markets around the world ,” said Jerry Boxall, managing director, ACM-Pivotal Europe. “With our strong track record of supporting trials in emerging markets and the high calibre of our employees, we are in a great position to effectively address the unique needs of our clients and keep their trials on schedule. We are proud of our achievements and excited about our future growth.”
About ACM-Pivotal
ACM-Pivotal is the global central laboratory with an inherently flexible approach and a focus on precision to keep clinical research studies on schedule. The organization sets itself apart by its single focus on global central lab services. ACM-Pivotal is defining the industry standard by continually developing customer-centric processes and services. ACM-Pivotal’s global operations extend to more than 60 countries and offer a broad and customized menu of safety and specialty services for clinical trials. The organization performs 12 million tests each year, featuring more than 1,500 individual tests spanning all medical disciplines, including Pathology, Microbiology and Pharmacogenomics. For more information, visit www.acm-pivotal.com.
